2 results
Approved WMORecruiting
Primary objective:To establish the safety and toxicity profile of treatment with Ho-166-PLLA-MS.Secondary objectives:• To evaluate tumor response. • To evaluate patient dosimetry. • To evaluate performance status.• To evaluate Quality of Life (QOL…
Approved WMORecruiting
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…